CTLA4 and hepatocellular carcinoma: Furthermore, PD-1 blockade in vivo was well-tolerated and promoted virus control in a subset of HCV-infected patients (54) whereas CTLA-4 blockade in patients with hepatocellular carcinoma and chronic hepatitis C was tolerated with antiviral and immune stimulatory effects (32).